John and Lucille van Geest Biomarker Facility

Proteo-Metabolomics Biomarker Facility

The John and Lucille van Geest Biomarker facility was established in 2013 thanks to a generous £2.5 million donation from the John and Lucille van Geest Foundation. This initial investment laid the foundation for the establishment of a facility dedicated to the discovery and development of cardiovascular biomarkers. Final logo

The support of J&L van Geest foundation has led to:

The establishment of a state of the art proteomics and metabolomics laboratory, investigating the use of biomarkers for diagnosis, prognosis and therapeutic monitoring of cardiovascular disease.

It is one of only a few such laboratories dedicated to cardiovascular research in the UK.

The requirement for biomarkers is especially important in heart failure and in coronary artery disease, where there are difficulties in making the diagnosis in some situations. Furthermore, the laboratory is also investigating the use of novel biomarkers for prognosis of heart failure and heart attacks, so that patients with a likely poor outcome could be selected and targeted for more intensive interventions.

The laboratory is also a major contributor to an FP7 European initiative to detect patients who respond poorly to heart failure therapies (Biostat programme), so that such patients could receive further monitoring.


Research facility

Current projects

Group members


Latest news

Share this page: